TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11147733

Group type: EXPERIMENTAL
Intervention: Disposable extended-wear
Number of subjects: 50

Group type: COMPARATOR
Intervention: Daily-disposable
Number of subjects: 50
Study: 9301443

Group type: EXPERIMENTAL
Intervention: GM-CSF, 300 micrograms/day administered subcutaneously on days 3-6, 10-13, 17-20, and 24-27 during chemotherapy
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo administered during chemotherapy
Number of subjects: 41
Study: 8421111

Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine, 100 ppm fluoride mouthrinse, rinsed 2x per day for 1 min with 15 ml for 6 weeks
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control rinse (minus active)
Number of subjects: 102
Study: 3950051

Group type: EXPERIMENTAL
Intervention: Trimoprostil 0.25 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trimoprostil 0.75 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trimoprostil 1.5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trimoprostil 3.0 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trimoprostil (0.75 mg to 3.0 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26031804

Group type: EXPERIMENTAL
Intervention: Three home visits by a diabetes nurse
Number of subjects: 201

Group type: COMPARATOR
Intervention: One telephone consultation (control group)
Number of subjects: 201
Study: 24397879

Group type: EXPERIMENTAL
Intervention: Serum cystatin C measured at the end of operation (T4)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Serum cystatin C measured 24 hours postoperatively (T5)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Preoperative serum cystatin C (T1)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Intraoperative serum cystatin C (T2/T3)
Number of subjects: 70
Study: 22422589

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) using drug-eluting stents (DES) (n=556)
Number of subjects: 865

Group type: COMPARATOR
Intervention: Coronary artery bypass graft (CABG) (n=309)
Number of subjects: 865

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) using DES (n=556)
Number of subjects: 865

Group type: EXPERIMENTAL
Intervention: Complex stenting (n=196)
Number of subjects: 865

Group type: COMPARATOR
Intervention: Simple stenting (n=360)
Number of subjects: 865
Study: 20581352

Group type: COMPARATOR
Intervention: NaF mouthrinse (500 ppm F⁻)
Number of subjects: 24

Group type: COMPARATOR
Intervention: AmF/NaF/SnCl₂ mouthrinse (500 ppm F⁻, 800 ppm Sn(2+))
Number of subjects: 24
Study: 18672531

Group type: EXPERIMENTAL
Intervention: NVP 400 mg per day
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: NVP 600 mg per day
Number of subjects: 32
Study: 16306519

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (1000 mg per day, increased to 3000 mg per day)
Number of subjects: 140
Study: 12475577

Group type: EXPERIMENTAL
Intervention: Short-term low-dose heparin plus bedrest
Number of subjects: 10

Group type: COMPARATOR
Intervention: Pregnant controls
Number of subjects: 10
Study: 10390746

Group type: EXPERIMENTAL
Intervention: Alpha interferon
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 8777623

Group type: EXPERIMENTAL
Intervention: MINS vasectomy
Number of subjects: 89

Group type: COMPARATOR
Intervention: Standard vasectomy
Number of subjects: 89
Study: 1503287

Group type: EXPERIMENTAL
Intervention: Cefamandole intravenously every four hours, three times, starting from induction of anaesthesia (1.5 g for <60 kg, 2.5 g for 60-80 kg, 3 g for >80 kg)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Placebo administered at the same times
Number of subjects: 114
Study: 6434168

Group type: COMPARATOR
Intervention: 2% sodium cromoglycate ophthalmic solution
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 4% sodium cromoglycate ophthalmic solution
Number of subjects: 40
Study: 31383366

Group type: EXPERIMENTAL
Intervention: Insulin Glargine U100
Number of subjects: 34

Group type: COMPARATOR
Intervention: NPH Insulin
Number of subjects: 34
Study: 30128938

Group type: EXPERIMENTAL
Intervention: Proprioceptive neuromuscular facilitation (PNF)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Standard rehabilitation
Number of subjects: 42
Study: 27792720

Group type: EXPERIMENTAL
Intervention: simvastatin plus inulin (20 mg simvastatin, 7 g inulin)
Number of subjects: 60

Group type: COMPARATOR
Intervention: simvastatin plus ezetimibe (20 mg simvastatin, 10 mg ezetimibe)
Number of subjects: 60
Study: 24984088

Group type: EXPERIMENTAL
Intervention: Uni-nostril breathing (UNB)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Dual-nostril paced breathing (PB)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 12
Study: 23046608

Group type: COMPARATOR
Intervention: Paroxetine (24 weeks)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Trauma-Focused Cognitive Behavioral Therapy (TF-CBT) (10-12 weeks)
Number of subjects: 90
Study: 20059361

Group type: EXPERIMENTAL
Intervention: Colesevelam 3.75 grams/day
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 17586424

Group type: EXPERIMENTAL
Intervention: n-3 PUFA (2.4 g daily for 8 weeks)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control (olive oil, 2.4 g daily for 8 weeks)
Number of subjects: 46
Study: 16304214

Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Nitroglycerin
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside
Number of subjects: 45
Study: 12208577

Group type: EXPERIMENTAL
Intervention: Post-operative external radiotherapy
Number of subjects: 0
Study: 10023787

Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.5 mg/kg/d for 1 week, then tapered over 3 weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (saline placebo)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control
Number of subjects: 40
Study: 8588068

Group type: EXPERIMENTAL
Intervention: Zileuton (5-lipoxygenase inhibitor)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2216227

Group type: EXPERIMENTAL
Intervention: Topical bupivacaine hydrochloride on both fallopian tubes
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Topical bupivacaine hydrochloride on the right fallopian tube only
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Topical bupivacaine hydrochloride on the left fallopian tube only
Number of subjects: 64

Group type: COMPARATOR
Intervention: No treatment (controls)
Number of subjects: 64
Study: 342438

Group type: EXPERIMENTAL
Intervention: Nomifensine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Nortriptyline
Number of subjects: 40
Study: 31194960

Group type: EXPERIMENTAL
Intervention: Biting activity of An. gambiae s.l. outdoors
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Biting activity of An. funestus s.l. outdoors
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Biting activity of An. funestus s.l. indoors
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Biting activity of An. gambiae s.l. during wet season
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Biting location preference of An. gambiae s.l.
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Biting location preference of An. funestus s.l. during wet season
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Biting location preference of An. funestus s.l. during dry season
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Protection from malaria vectors by LLINs
Number of subjects: 12
Study: 28785809

Group type: EXPERIMENTAL
Intervention: Mud-bath therapy (MBT) group: daily treated with a combination of local mud-packs at 42 °C and baths in mineral water at 37 °C for 15 min, for 12 applications over a period of 2 weeks, in addition to standard therapy.
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group: continued their conventional treatment alone.
Number of subjects: 32
Study: 25874654

Group type: EXPERIMENTAL
Intervention: Public sector costs
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: National cash-for-care allowance
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: Drug prescriptions
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: Out-of-pocket expenditure for private care workers
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: Value of informal care
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: Socioeconomic factors
Number of subjects: 438
Study: 24132057

Group type: EXPERIMENTAL
Intervention: Bright light + melatonin capsule
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bright light + placebo capsule
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dim light (placebo) + melatonin capsule
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dim light (placebo) + placebo capsule
Number of subjects: 0

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined bright light + melatonin treatment
Number of subjects: 0
Study: 21142615

Group type: EXPERIMENTAL
Intervention: PIO + SU
Number of subjects: 2388

Group type: EXPERIMENTAL
Intervention: PIO + MET
Number of subjects: 2388

Group type: COMPARATOR
Intervention: SU + MET
Number of subjects: 2388
Study: 19175712

Group type: EXPERIMENTAL
Intervention: Lafutidine 10 mg twice daily for 12 weeks plus gargling with azulene sulfonate sodium (ASS)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Previous H2RAs plus ASS gargling (control group)
Number of subjects: 71
Study: 17069835

Group type: EXPERIMENTAL
Intervention: New ST-segment elevation of 0.1 mV or greater
Number of subjects: 506
Study: 15482043

Group type: EXPERIMENTAL
Intervention: Family-focused preventive intervention combined with academic tutoring
Number of subjects: 424

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 424
Study: 16394041

Group type: EXPERIMENTAL
Intervention: Water-based lubricant (0.5 mL contaminated specimen)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control (non-contaminated specimen)
Number of subjects: 200
Study: 10393617

Group type: EXPERIMENTAL
Intervention: Weight-bearing physical activity program
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 9
Study: 9171503

Group type: EXPERIMENTAL
Intervention: IPS-Empress inlays and onlays
Number of subjects: 36
Study: 1759375

Group type: EXPERIMENTAL
Intervention: Balneotherapy with psychotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Balneotherapy without psychotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo treatment with psychotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo treatment without psychotherapy
Number of subjects: 0
Study: 6176753

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy (Velban, Bleomycin, Cis-Platinum, Ifosfamid)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Supportive care
Number of subjects: 25
Study: 31549922

Group type: COMPARATOR
Intervention: Traditional CHO replacement (TRAD)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Train-high sleep-low (THSL)
Number of subjects: 8
Study: 29396016

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (routine care only)
Number of subjects: 100
Study: 27485852

Group type: EXPERIMENTAL
Intervention: Leicester Practice Computer Risk Score (LPCRS)
Number of subjects: 577

Group type: COMPARATOR
Intervention: Leicester Self‐Assessment Score (LSAS)
Number of subjects: 577

Group type: EXPERIMENTAL
Intervention: LPCRS
Number of subjects: 577

Group type: COMPARATOR
Intervention: LSAS
Number of subjects: 577
Study: 25153429

Group type: EXPERIMENTAL
Intervention: e-PBL program consisting of eight tutorials
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 32
Study: 22210451

Group type: EXPERIMENTAL
Intervention: Glazing techniques (five glazing ceramics applied and fired)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Resin based cement alone (Control Group A)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Storage regimes (wet storage vs thermocycling)
Number of subjects: 110
Study: 20107305

Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 0
Study: 17413907

Group type: COMPARATOR
Intervention: Remifentanil 0 ng/ml
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Remifentanil 2 ng/ml
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Remifentanil 4 ng/ml
Number of subjects: 45
Study: 16117181

Group type: EXPERIMENTAL
Intervention: Energising drink (caffeine and glucose)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo drink
Number of subjects: 40
Study: 12118653

Group type: EXPERIMENTAL
Intervention: Tubal factor infertility
Number of subjects: 749

Group type: EXPERIMENTAL
Intervention: Male factor infertility
Number of subjects: 749

Group type: EXPERIMENTAL
Intervention: Anovulation
Number of subjects: 749

Group type: EXPERIMENTAL
Intervention: Endometriosis
Number of subjects: 749

Group type: EXPERIMENTAL
Intervention: Unexplained infertility
Number of subjects: 749
Study: 10459691

Group type: EXPERIMENTAL
Intervention: Methylcobalamin (Met-12) - large dosage
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group - small dosage
Number of subjects: 0
Study: 7778622

Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 gel (0.5 mg, three doses 6 hours apart)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Estradiol cream (4 mg, three doses 6 hours apart)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Oxytocin (at induction per protocol with an infusion pump)
Number of subjects: 99
Study: 2202480

Group type: EXPERIMENTAL
Intervention: Mebendazole
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Albendazole
Number of subjects: 55
Study: 31382005

Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation (FES) during walking for 1 hour on a supervised treadmill
Number of subjects: 168

Group type: COMPARATOR
Intervention: Control group (nondiabetic patients)
Number of subjects: 168
Study: 28881480

Group type: EXPERIMENTAL
Intervention: Hypomineralized second primary molars (HSPM)
Number of subjects: 623

Group type: EXPERIMENTAL
Intervention: HSPM
Number of subjects: 623
Study: 27018069

Group type: EXPERIMENTAL
Intervention: Enzalutamide 160 mg/day
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 24503408

Group type: EXPERIMENTAL
Intervention: 10 mg/mL posterior subtenon injection of nanoparticle carboplatin
Number of subjects: 6
Study: 22215165

Group type: EXPERIMENTAL
Intervention: Low protein diet (5% of energy from protein)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Normal protein diet (15% of energy from protein)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: High protein diet (25% of energy from protein)
Number of subjects: 25
Study: 20300029

Group type: EXPERIMENTAL
Intervention: Hypoxic exposure for 2 nights
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Hypoxic exposure for 2 days + nights
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control session (1 week before or after altitude session)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Hypoxic exposure
Number of subjects: 13
Study: 17214524

Group type: EXPERIMENTAL
Intervention: Conventional Le Fort I osteotomy
Number of subjects: 22

Group type: COMPARATOR
Intervention: Le Fort I distraction
Number of subjects: 22
Study: 15870641

Group type: EXPERIMENTAL
Intervention: Variable intensity (VAR) Spinning protocol
Number of subjects: 15

Group type: COMPARATOR
Intervention: Constant intensity (CON)
Number of subjects: 15
Study: 12000487

Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 16

Group type: COMPARATOR
Intervention: Fluticasone
Number of subjects: 16
Study: 9802848

Group type: EXPERIMENTAL
Intervention: Thiopental
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 20
Study: 9098274

Group type: EXPERIMENTAL
Intervention: Corticosteroid treatment after trabeculectomy
Number of subjects: 35

Group type: COMPARATOR
Intervention: Nonsteroid treatment after trabeculectomy
Number of subjects: 35
Study: 2487533

Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg/day
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg/day
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Simvastatin with cholestyramine
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Simvastatin with bezafibrate
Number of subjects: 44
Study: 648206

Group type: EXPERIMENTAL
Intervention: Ephedrine
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 31788828

Group type: EXPERIMENTAL
Intervention: Field-directed thulium laser (TL)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Combination thulium laser and photodynamic therapy (TL-PDT)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Thulium laser (TL)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Lesion-directed curettage control
Number of subjects: 12
Study: 30978265

Group type: EXPERIMENTAL
Intervention: Aprepitant therapy
Number of subjects: 32

Group type: COMPARATOR
Intervention: Standard antiemetic therapy
Number of subjects: 32
Study: 28449280

Group type: EXPERIMENTAL
Intervention: ondansetron 150 μg.kg‐1
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: droperidol 10 μg.kg‐1
Number of subjects: 300

Group type: COMPARATOR
Intervention: saline
Number of subjects: 300
Study: 25577522

Group type: EXPERIMENTAL
Intervention: MR-guided core needle biopsy using DCE targeting
Number of subjects: 53
Study: 24084214

Group type: EXPERIMENTAL
Intervention: Irbesartan (angiotensin receptor blocker)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Atenolol (beta-adrenergic receptor blocker)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Normotensive group
Number of subjects: 114

Group type: COMPARATOR
Intervention: Hypertensive heart disease group
Number of subjects: 114
Study: 20863418

Group type: EXPERIMENTAL
Intervention: SCGOS/LCFOS/AOS
Number of subjects: 113

Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Both groups (SCGOS/LCFOS/AOS and placebo)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Low BW
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Exclusive breast milk feeding
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Mixed breast milk/formula feeding
Number of subjects: 113
Study: 18197403

Group type: EXPERIMENTAL
Intervention: Celecoxib (200 mg twice daily)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 16292089

Group type: EXPERIMENTAL
Intervention: Regular dose of omeprazole (20 mg; 60 mg/3 days)
Number of subjects: 142

Group type: COMPARATOR
Intervention: High dose of omeprazole (80 mg bolus + 8 mg/h; 652 mg/3 days)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Regular dose of omeprazole
Number of subjects: 142

Group type: COMPARATOR
Intervention: High dose of omeprazole
Number of subjects: 142
Study: 12465390

Group type: EXPERIMENTAL
Intervention: HCFU 300 mg/day orally from day 14 for a year, plus intravenous mitomycin C (MMC) 6 mg/m2 on day 0 and 7 after surgery.
Number of subjects: 326

Group type: COMPARATOR
Intervention: Intravenous mitomycin C (MMC) 6 mg/m2 on day 0 and 7 after surgery.
Number of subjects: 326
Study: 10622542

Group type: EXPERIMENTAL
Intervention: No-touch technique (SV harvested with surrounding tissue, left in situ, covered with saline-soaked compress, stored in heparinized blood)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional technique (adventitial stripping of the vein, manual distention, storing in saline)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intermediate technique (adventitial stripping, left in situ, covered with papaverine-soaked compress, stored in heparinized blood)
Number of subjects: 0
Study: 8554937

Group type: EXPERIMENTAL
Intervention: 5 mg 8‐MOP
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 10 mg 8‐MOP
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 15 mg 8‐MOP
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 7.5 mg 8‐MOP added to 300 ml platelet concentrate
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Intravenous administration of 7.5 mg 8‐MOP over 60 min
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: All doses of 8‐MOP
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Pharmacokinetic models
Number of subjects: 18
Study: 1838256

Group type: EXPERIMENTAL
Intervention: 2% ketoconazole cream (Nizoral)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Bland cream (control)
Number of subjects: 60
Study: 6117584

Group type: EXPERIMENTAL
Intervention: Placebo injection (holiday group)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Regular medication (control group)
Number of subjects: 31
Study: 29550235

Group type: EXPERIMENTAL
Intervention: Early Limited Formula (ELF), 10 mL of formula after each breastfeeding until copious maternal milk production
Number of subjects: 164

Group type: COMPARATOR
Intervention: Control group (exclusive breastfeeding)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Early Limited Formula (ELF)
Number of subjects: 164
Study: 28793919

Group type: EXPERIMENTAL
Intervention: Family based intervention program including supervised exercise (3 days/week, 90 min per session)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Family based lifestyle education and psycho-educational program (2 days/month)
Number of subjects: 84
Study: 26349843

Group type: EXPERIMENTAL
Intervention: Topical tranexamic acid (25 mg/ml)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 30
Study: 24016502

Group type: COMPARATOR
Intervention: Intensive medical therapy (IMT)
Number of subjects: 1605

Group type: COMPARATOR
Intervention: Bare-metal stents (BMS)
Number of subjects: 1605

Group type: COMPARATOR
Intervention: Drug-eluting stents (DES)
Number of subjects: 1605
Study: 21099666

Group type: EXPERIMENTAL
Intervention: Immediate switch to etravirine (ETR)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Delayed switch (placebo)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Combined (both arms)
Number of subjects: 38
Study: 18236463

Group type: EXPERIMENTAL
Intervention: High-dose beta interferon-1a
Number of subjects: 28